---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-104102"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:34:42.869663+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics reports FY2025 loss from ops $36.1M; cash $31.8M into 2027

## Summary
- Collaboration revenue $7.7M for FY2025, flat YoY; Q4 2025 revenue $2.5M vs $0 in Q4 2024.
- R&D expenses $28.5M in FY2025, down from $57.5M in FY2024; G&A $13.8M vs $18.5M, driven by restructuring.
- Loss from operations $36.1M for FY2025 vs $73.0M in FY2024.
- Cash, cash equivalents and marketable securities $31.8M as of Dec 31, 2025; expected to fund milestones into 2027.
- Initial clinical data for BDC-4182 Phase 1 study (CLDN18.2) expected in Q3 2026; step-up dosing added to protocol.

## SEC filing metadata
- accession: 0001193125-26-104102
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/0001193125-26-104102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/bolt-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-104102
- JSON: https://secwatch.observer/filing/0001193125-26-104102.json
- Plain text: https://secwatch.observer/filing/0001193125-26-104102.txt

## Key facts
- Earnings Releases
  Bolt Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.5 million.
  - Period: the fourth quarter ended December 31, 2025
  - Revenue: $2.5 million
  - Result: reported results
  source text: Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/0001193125-26-104102-index.htm
- Earnings Releases
  Bolt Biotherapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $7.7 million.
  - Period: the full year ended December 31, 2025
  - Revenue: $7.7 million
  - Result: reported results
  source text: Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/0001193125-26-104102-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.